Related Experiment Video
Updated: Sep 18, 2025
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
83.9K
Factor XIa Inhibitors Versus Direct Oral Anticoagulants for Atrial Fibrillation: A Systematic Review and
Sufyan Shahid1, Minahil Iqbal2, Mariam Shahabi3
1Khawaja Muhammad Safdar Medical College, Sialkot, Pakistan.
Cardiovascular Drugs and Therapy
|June 25, 2025
Summary
Factor XIa inhibitors reduce bleeding risk in atrial fibrillation (AF) patients compared to direct oral anticoagulants (DOACs), but increase ischemic stroke risk. Mortality and hemorrhagic stroke risks were similar between the two treatments.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Clinical Trials
Background:
- Direct oral anticoagulants (DOACs) are standard for thromboembolic risk reduction in atrial fibrillation (AF).
- Bleeding complications remain a significant concern with DOAC therapy.
- Factor XIa inhibitors are emerging as a potential alternative, but their comparative efficacy and safety are not fully established.
Purpose of the Study:
- To systematically review and meta-analyze randomized controlled trials (RCTs).
- To compare the efficacy and safety of Factor XIa inhibitors against DOACs in AF patients.
- To evaluate risks of thromboembolic events and bleeding.
Main Methods:
- Systematic literature search of PubMed, Embase, and Cochrane Library until February 2025.
- Inclusion of three RCTs involving 16,845 AF patients.
- Pooled risk ratios (RR) using random-effects models and assessed study quality with RoB 2 tool.
Main Results:
- Factor XIa inhibitors showed a significantly higher risk of ischemic stroke (RR: 3.32) compared to DOACs.
- Factor XIa inhibitors demonstrated a lower risk of major/clinically relevant non-major bleeding (RR: 0.41) and minor bleeding (RR: 0.68).
- No significant differences were observed in all-cause mortality, cardiovascular mortality, or hemorrhagic stroke risk.
Conclusions:
- Factor XIa inhibitors offer reduced bleeding risk but an increased risk of ischemic stroke versus DOACs in AF.
- No significant differences in hemorrhagic stroke or overall mortality were found.
- Further research is needed to clarify the net clinical benefit of Factor XIa inhibitors.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
924
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
924
01:29Venous Thrombosis III: Interprofessional Care
28
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
28
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
655
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
655
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.3K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.3K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
849
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
849